Analysts Update Their Price Forecasts For 89bio Inc (ETNB)

89bio Inc (ETNB) concluded trading on Thursday at a closing price of $7.03, with 4.66 million shares of worth about $32.73 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -17.49% during that period and on December 19, 2024 the price saw a loss of about -7.62%. Currently the company’s common shares owned by public are about 117.58M shares, out of which, 112.92M shares are available for trading.

Stock saw a price change of -10.45% in past 5 days and over the past one month there was a price change of -12.02%. Year-to-date (YTD), ETNB shares are showing a performance of -37.06% which decreased to -35.21% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $7.00 but also hit the highest price of $16.63 during that period. The average intraday trading volume for 89bio Inc shares is 820.10K. The stock is currently trading -15.14% below its 20-day simple moving average (SMA20), while that difference is down -16.42% for SMA50 and it goes to -20.46% lower than SMA200.

89bio Inc (NASDAQ: ETNB) currently have 117.58M outstanding shares and institutions hold larger chunk of about 89.22% of that.

The stock has a current market capitalization of $826.60M and its 3Y-monthly beta is at 1.06. It has posted earnings per share of -$2.91 in the same period. It has Quick Ratio of 11.65 while making debt-to-equity ratio of 0.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ETNB, volatility over the week remained 9.17% while standing at 6.86% over the month.

Stock’s fiscal year EPS is expected to drop by -58.84% while it is estimated to increase by 7.70% in next year. EPS is likely to grow at an annualized rate of 11.00% for next 5-years, compared to annual growth of -11.24% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on April 22, 2024 offering a Buy rating for the stock and assigned a target price of $30 to it. Coverage by RBC Capital Mkts stated 89bio Inc (ETNB) stock as a Sector perform in their note to investors on January 12, 2024, suggesting a price target of $15 for the stock. On October 10, 2023, Oppenheimer Downgrade their recommendations, while on August 28, 2023, UBS Initiated their ratings for the stock with a price target of $36. Stock get an Outperform rating from Evercore ISI on June 13, 2023.

Most Popular

Related Posts